eligibility_summary
Eligibility: Adults ≥18 with ECOG 0–1 and adequate organ/marrow function, able to understand, consent, and comply. Must have cytologic/histologic and radiologic confirmation of an inoperable, locally advanced, metastatic, or recurrent solid tumor. Cohort expansion will include multiple tumor types: NSCLC, HR+ breast cancer, head and neck cancer, esophageal squamous cell carcinoma, and triple-negative breast cancer.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Drugs/Interventions: XB010 (IV investigational immunotherapy, specific target/mechanism not disclosed in this record) tested as monotherapy and with pembrolizumab, Pembrolizumab (IV anti–PD-1 monoclonal antibody checkpoint inhibitor) blocks PD-1 to restore antitumor T‑cell activity. Cells/Pathways targeted: Pembrolizumab targets PD‑1 on T cells, relieving PD‑1/PD‑L1–mediated inhibition to enhance immune attack in the tumor microenvironment. The cellular target and pathway for XB010 are not specified in the trial listing.